IP Library Granted Patent US 9,381,216
Granted Patent B2
US 9,381,216 · App. 12/452,767 · Granted Jul 5, 2016

Methods of generating, repairing and/or maintaining connective tissue in vivo

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,381,216
App. No.
12/452,767
Granted
Jul 5, 2016
Kind
B2
Abstract

This invention relates to a method for generating, repairing and/or maintaining connective tissue in a subject. In one embodiment, the invention relates to a method for generating, repairing and/or maintaining cartilage tissue in a subject. The present invention also relates to a method of treating and/or preventing a disease in a subject arising from degradation and inflammation of connective tissue.

Claims (14)

1. A method of treating a disease in a subject arising from degradation and/or inflammation of connective tissue, the method comprising administering to the subject a population of cells which have bright been enriched for STRO-1 bright multipotential cells or progeny cells thereof, wherein paracrine activities of the administered population of cells protect or stimulate growth and/or regeneration of the connective tissue wherein the disease is selected from the group consisting of osteoarthritis, rheumatoid arthritis, psoriatic arthritis, seronegative arthritis, and arthritis associated with inflammatory bowel disease, and bright wherein the population of cells enriched for STRO-1 bright multipotential cells or progeny cells thereof are administered by intra-articular injection to a joint space of the subject, wherein the joint space is in a knee joint, hip joint, ankle joint, shoulder joint, elbow joint, wrist joint, hand or finger joint or a joint of the foot; and wherein the administration of the population of cells enriched for STRO-1 bright multipotential cells or progeny cells thereof results in preservation or generation of connective tissue that is rich in proteoglycans in the joint space of the subject.

2. The method of claim 1 , wherein the connective tissue is rich in proteoglycans.

3. The method of claim 1 , wherein the connective tissue is cartilage.

4. The method of claim 3 , wherein the disease results in one or more defects in the cartilage.

5. The method of claim 1 , wherein the connective tissue that is rich in proteoglycans is hyaline cartilage.

6. The method of claim 1 , which further comprises administering a chondroprotective agent.

7. The method of claim 6 , wherein the chondroprotective agent is hyaluronic acid (HA).

8. A method of treating a disease in a subject arising from degradation and/or inflammation of connective tissue, comprising administering to the subject a population of cells enriched for STRO-1 bright multipotential cells or progeny cells thereof, wherein the disease is selected from the group consisting of osteoarthritis, rheumatoid arthritis, psoriatic arthritis, seronegative arthritis, and arthritis associated with inflammatory bowel disease, wherein the population of cells enriched for STRO-1 bright multipotential cells or progeny cells thereof are administered to a joint space, and wherein the joint space is in a knee joint, hip joint, ankle joint, shoulder joint, elbow joint, wrist joint, hand or finger joint or a joint of the foot; and wherein the administration of the population of cells enriched for STRO-1 bright cells or progeny cells thereof results in preservation or generation of connective tissue that is rich in proteoglycans in the joint space of the subject.

9. The method of claim 8 , wherein the connective tissue is cartilage.

10. The method of claim 9 , wherein the disease results in one or more defects in the cartilage.

11. The method of claim 8 , wherein the population of cells enriched for STRO-1 bright multipotential cells or progeny cells thereof are administered by intra-articular injection.

12. The method of claim 8 , wherein the connective tissue that is rich in proteoglycans is hyaline cartilage.

13. The method of claim 8 , which further comprises administering a chondroprotective agent.

14. The method of claim 13 , wherein the chondroprotective agent is hyaluronic acid (HA).

Assignments (5)
RELEASE OF SECURITY INTEREST IN INTELLECTUAL PROPERTY Recorded Jan 2, 2026
From: OAKTREE FUND ADMINISTRATION, LLC, AS AGENT
To: MESOBLAST LIMITED; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
Reel/Frame 074174/0183 →
RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT AT REEL/FRAME NO. 45759/0682 Recorded Jul 30, 2025
From: HERCULES CAPITAL, INC., AS AGENT
To: MESOBLAST, INC.
Reel/Frame 072294/0555 →
SECURITY INTEREST Recorded Dec 10, 2021
From: MESOBLAST LIMITED ACN 109 431 870; MESOBLAST UK LIMITED; MESOBLAST, INC. (FORMERLY KNOWN AS ANGIOBLAST, INC.); MESOBLAST INTERNATIONAL SÀRL
To: OAKTREE FUND ADMINISTRATION, LLC
Reel/Frame 058957/0447 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Mar 28, 2018
From: MESOBLAST, INC.
To: HERCULES CAPITAL, INC., AS ADMINISTRATIVE AND COLLATERAL AGENT
Reel/Frame 045759/0682 →
CHANGE OF NAME Recorded May 10, 2012
From: ANGIOBLAST SYSTEMS, INC.
To: MESOBLAST, INC.
Reel/Frame 028192/0789 →